TITLE:
Thiol-Disulphide Balance: Could Be a New Marker for Thyroid Cancer?
AUTHORS:
Ayşe Özdemir, Özcan Erel
KEYWORDS:
Disulphide, Thiol, Tumor Marker, Thyroid Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.9 No.8,
August
16,
2018
ABSTRACT: Objectives. Cancer is a very widespread disorder known in world wide since long, but its
biochemical features remain unclear. Thyroid carcinomas are the most common endocrine cancer and its
frequency continues to escalate. There is evidence that the serum concentration
of TSH is an unreliant predictor for the diagnosis of thyroid cancer. The
formation of the plasma thiol pool from low
and large molecular weight proteins suggests that thiol/disulfide
balance is important in cancerous cases. The aim of this study was to investigate
an oxidative stress marker (thiol/disulphide homeostasis) and IMA (Ischemia
modified albumin), Albumin, CEA (Carcinoembryonic antigen), TSH (Thyroid
stimulate hormone), thyroxine (T4), free thyroxine (FT4),
triiodothyronine (T3) and free triiodothyronine (FT3) in
patients with thyroid cancer and compare the results with healthy controls for
the first time in literature. Materials-Methods: A total of 43
participants including 23 patients with thyroid cancer and 20 healthy
individuals were included in the study. Serum levels of TSH, T4, FT4,
T3 and FT3 have been measured during treatment and
follow-up of patients with thyroid carcinoma. Serum levels of TSH, T4,
FT4, T3 and FT3, IMA, Albumin, CEA, Native
thiol (-SH), disulfide (-S-S) and total thiol (TT) as well as disulphide/native
thiol and disulphide/total thiol ratios were compared between the groups.
Native thiol, disulfide and total thiol concentrations were measured with a
novel automated method (Roche, cobas 501, Mannheim, Germany). Results and
conclusion: This paper discusses an oxidative stress marker
(thiol/disulphide homeostasis) and tumor markers IMA, Albumin, CEA, TSH, T4,
FT4, T3 and FT3 in patients with thyroid cancer
and compare the results with healthy controls. Mean age at participant was
41.73 years for thyroid cancer patients (21 females/2 males). A
control group of 20 participants was
included the study (19 females/1
male, mean age 51.75).